Patents Examined by Kauser M Akhoon
-
Patent number: 10946104Abstract: Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an MHC-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes. The provided immunoglobulins provided with a toxic moiety are of particular use in pharmaceutical compositions for the treatment of diseases related to cellular aberrancies, such as cancers and autoimmune diseases.Type: GrantFiled: January 11, 2013Date of Patent: March 16, 2021Assignee: APO-TB.V.Inventors: Johan Renes, Paul Steverink, Ralph Alexander Willemsen
-
Patent number: 10898579Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: June 28, 2016Date of Patent: January 26, 2021Assignee: IMMUNOGEN, INC.Inventors: Nicholas C. Yoder, Chen Bai, Michael Louis Miller
-
Patent number: 10874739Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.Type: GrantFiled: December 20, 2019Date of Patent: December 29, 2020Assignee: The Unites States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka, Hisataka Kobayashi
-
Patent number: 10836821Abstract: There is disclosed an improved ADC (antibody drug conjugate) type composition having at least two different drug payloads conjugated to a single targeting protein. More specifically, the present disclosure attaches a first drug conjugate to a dual Cysteine residue on a targeting protein and a second drug conjugate with a different drug to a Lys residue on the targeting protein.Type: GrantFiled: October 15, 2014Date of Patent: November 17, 2020Assignee: Sorrento Therapeutics, Inc.Inventors: Zhenwei Miao, Gang Chen, Tong Zhu, Alisher B. Khasanov, Yufeng Hong, Hong D. Zhang, Alexander Chucholowski
-
Patent number: 10821179Abstract: A protein, e.g. an antibody, coated with a non-immunogenic molecule selected from an amino-monosaccharide-biotin adduct or a monosaccharide-biotin adduct is disclosed, wherein the coated protein, which has diminished immunogenicity relative to the uncoated protein and intact biological activity, enables, for example, cross-species vaccination.Type: GrantFiled: November 4, 2015Date of Patent: November 3, 2020Assignee: GAVISH-GALILEE BIO APPLICATIONS, LTD.Inventors: Jacob Pitcovski, Jacob Vaya, Soliman Khatib, Elina Aizenshtein, Tal Gefen
-
Patent number: 10800856Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.Type: GrantFiled: June 7, 2013Date of Patent: October 13, 2020Assignee: Ambrx, Inc.Inventors: Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck, Ying Sun
-
Patent number: 10794802Abstract: In various embodiments, the present application teaches methods for tissue clearing in which tissues are rendered macromolecule-permeable and optically-transparent, thereby exposing their cellular structure with intact connectivity. In some embodiments, the present application teaches ePACT, which is a protocol for enhanced tissue clearing via expansion. In some embodiments, the present application teaches visualizing a tissue that has been expanded via ePACT.Type: GrantFiled: August 17, 2016Date of Patent: October 6, 2020Assignee: California Institute of TechnologyInventors: Viviana Gradinaru, Jennifer Treweek
-
Patent number: 10745488Abstract: The present invention relates to an antibody comprising a GlcNAc-S(A)x substituent, wherein S(A)x is a sugar derivative comprising x functional groups A wherein A is independently selected from the group consisting of an azido group, a keto group and an alkynyl group and x is 1, 2, 3 or 4, wherein said GlcNAc-S(A)x substituent is bonded to the antibody via CI of the N-acetylglucosamine of said GlcNAc-S(A)x substituent, and wherein said N-acetylglucosamine is optionally fucosylated. The invention also relates to an antibody-conjugate, in particular to an antibody-conjugate according to the Formula (20) or (20b), wherein AB is an antibody, S is a sugar or a sugar derivative, D is a molecule of interest, and wherein said N-acetylglucosamine is optionally fucosylated (b is 0 or 1). The invention further relates to a process for the preparation of a modified antibody, to a process for the preparation of an antibody-conjugate, and to said antibody-conjugate for use as a medicament.Type: GrantFiled: October 23, 2013Date of Patent: August 18, 2020Assignee: SYNAFFIX B.V.Inventors: Floris Louis Van Delft, Remon Van Geel, Maria Antonia Wijdeven
-
Patent number: 10729782Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP- wherein the antibody is connected to the terminal of L1, the antitumor compound is connected to the terminal of Lc or LP, and any one or two or more of linkers of L1, L2, and LP has a hydrophilic structure.Type: GrantFiled: November 22, 2017Date of Patent: August 4, 2020Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Takashi Nakada, Masao Yoshida, Shinji Ashida, Takeshi Masuda, Hideki Miyazaki, Yuji Kasuya, Yuki Abe, Yusuke Ogitani
-
Patent number: 10702526Abstract: The present disclosure relates to the use MNK-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressive cytokines, such as IL-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.Type: GrantFiled: April 15, 2016Date of Patent: July 7, 2020Assignee: eFFECTOR Therapeutics Inc.Inventors: Kevin R. Webster, Vikas Goel
-
Patent number: 10695371Abstract: The present invention relates to the use of a photoactivatable Porphyrin-Derivative in extracorporeal photophoresis (ECP) treatment, in which a patient's blood or part of it containing sad Porphyrin-derivative is/are exposed to light of a wavelength which activates said photoactivatable Porphyrin-Derivative.Type: GrantFiled: April 24, 2015Date of Patent: June 30, 2020Assignee: Oslo Universitetssykehus HFInventors: Qian Peng, Trond Warloe, Jahn M. Nesland, Eidi Christensen, Odrun Arna Gederaas, Toril Holien
-
Patent number: 10682330Abstract: In order to reduce the side effects of paclitaxel derivatives having excellent anti-cancer effects, an attempt was made to produce a liposome encapsulating paclitaxel derivatives such as paclitaxel monoglycosides and docetaxel monoglycosides. However, the introduction efficiency of paclitaxel derivatives, etc., into a liposome was poor, and this technique was not developed to a practical level. The present invention provides a method for producing a liposome encapsulating a paclitaxel monoglycoside and/or a docetaxel monoglycoside, and having an antibody specifically recognizing a cancer cell, the method comprising a step of bringing a liposome encapsulating a polyoxyethylene ester derivative, a lower alcohol, and a buffer or water into contact with a solution in which a paclitaxel monoglycoside and/or a docetaxel monoglycoside is dissolved in an alkylene glycol-containing buffer or water.Type: GrantFiled: March 22, 2013Date of Patent: June 16, 2020Assignees: ENSUIKO SUGAR REFINING CO., LTD., HIROKI HAMADA, YOSHIO SHIMIZU, NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Hiroki Hamada, Ichiro Fujiwara, Masaharu Seno, Tomonari Kasai, Tsukasa Shigehiro, Masaharu Murakami, Katsuhiko Mikuni
-
Patent number: 10668165Abstract: The present disclosure provides various molecular constructs having a targeting element and an effector element. Methods for treating various diseases using such molecular constructs are also disclosed.Type: GrantFiled: January 18, 2016Date of Patent: June 2, 2020Assignee: IMMUNWORK INC.Inventors: Tse-Wen Chang, Chien-Jen Lin, Hsing-Mao Chu
-
Patent number: 10618935Abstract: An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.Type: GrantFiled: November 2, 2016Date of Patent: April 14, 2020Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTEInventors: Yi-Ju Ko, Jheng-Sian Li, Maggie Lu, On Lee, Ping-Fu Cheng, Chun-Min Liu
-
Patent number: 10603387Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).Type: GrantFiled: October 31, 2017Date of Patent: March 31, 2020Assignee: Synthon Biopharmaceuticals B.V.Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
-
Patent number: 10576164Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, wherType: GrantFiled: October 17, 2017Date of Patent: March 3, 2020Assignees: MedImmune Limited, Genentech, Inc.Inventors: Philip Wilson Howard, John A. Flygare, Thomas Pillow, Binqing Wei
-
Patent number: 10570151Abstract: The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule-ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.Type: GrantFiled: March 14, 2014Date of Patent: February 25, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventor: Thomas Nittoli
-
Patent number: 10561729Abstract: Embodiments of near-infrared light-cleavable heptamethine cyanine-based conjugates, particularly targeting agent-drug conjugates, according to Formula I and conjugate precursors are disclosed. The disclosed targeting agent-drug conjugates are useful for targeted delivery and release of a drug. Methods of making and using the conjugates and precursors also are disclosed.Type: GrantFiled: August 7, 2017Date of Patent: February 18, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Martin John Schnermann, Roger Rauhauser Nani, Alexander Patrick Gorka
-
Patent number: 10550190Abstract: Phosphate-based linkers with tunable stability for intracellular delivery of drug conjugates are described. The phosphate-based linkers comprise a monophosphate, diphosphate, triphosphate, or tetraphosphate group (phosphate group) and a linker arm comprising a tuning element and optionally a spacer. A payload is covalently linked to the phosphate group at the distal end of the linker arm and the functional group at the proximal end of the linker arm is covalently linked to a cell-specific targeting ligand such as an antibody. These phosphate-based linkers have a differentiated and tunable stability in blood vs. an intracellular environment (e.g. lysosomal compartment).Type: GrantFiled: March 30, 2015Date of Patent: February 4, 2020Assignees: Merck Sharp & Dohme Corp., Ambrx, Inc.Inventors: Robert M. Garbaccio, Jeffrey Kern, Philip E. Brandish, Sanjiv Shah, Linda Liang, Ying Sun, Jianing Wang, Nick Knudsen, Andrew Beck, Anthony Manibusan, Dennis Gately
-
Patent number: 10548985Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors/cancers. Also provided are compositions comprising the compounds.Type: GrantFiled: January 8, 2015Date of Patent: February 4, 2020Assignee: Birdie Biopharmaceuticals, Inc.Inventor: Lixin Li